Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Titel:
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study
Auteur:
Baumert, Brigitta G Hegi, Monika E van den Bent, Martin J von Deimling, Andreas Gorlia, Thierry Hoang-Xuan, KhĂȘ Brandes, Alba A Kantor, Guy Taphoorn, Martin J B Hassel, Mohamed Ben Hartmann, Christian Ryan, Gail Capper, David Kros, Johan M Kurscheid, Sebastian Wick, Wolfgang Enting, Roelien Reni, Michele Thiessen, Brian Dhermain, Frederic Bromberg, Jacoline E Feuvret, Loic Reijneveld, Jaap C Chinot, Olivier Gijtenbeek, Johanna M M Rossiter, John P Dif, Nicolas Balana, Carmen Bravo-Marques, Jose Clement, Paul M Marosi, Christine Tzuk-Shina, Tzahala Nordal, Robert A Rees, Jeremy Lacombe, Denis Mason, Warren P Stupp, Roger